A sexual dysfunction and lower urinary tract symptoms have been a hot issue in recent years for scientists to study. There have been several clinical epidemiologic studies conducted in order to examine the connections between these two seemingly unrelated areas of urology research. In this review, an attempt is made to address these two sectors, their influence on patients’ quality of life, shared pathophysiological processes, and therapeutic features. Many urological patients suffer from both conditions, which are widespread in the general community. Phosphodiesterase type 5 inhibitors, the generally accepted combo therapy in this situation, sparked interest in finding alternative therapeutic choices.